KR101705547B1 - Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract - Google Patents
Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract Download PDFInfo
- Publication number
- KR101705547B1 KR101705547B1 KR1020130082310A KR20130082310A KR101705547B1 KR 101705547 B1 KR101705547 B1 KR 101705547B1 KR 1020130082310 A KR1020130082310 A KR 1020130082310A KR 20130082310 A KR20130082310 A KR 20130082310A KR 101705547 B1 KR101705547 B1 KR 101705547B1
- Authority
- KR
- South Korea
- Prior art keywords
- activity
- extract
- present
- bellflower
- drying
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 97
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 30
- 235000006753 Platycodon grandiflorum Nutrition 0.000 title abstract description 24
- 230000003078 antioxidant effect Effects 0.000 title abstract description 21
- 230000001093 anti-cancer Effects 0.000 title abstract description 18
- 239000003963 antioxidant agent Substances 0.000 title abstract description 17
- 240000003582 Platycodon grandiflorus Species 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 37
- 230000036541 health Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 241000588754 Klebsiella sp. Species 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 52
- 230000002000 scavenging effect Effects 0.000 abstract description 32
- 210000004027 cell Anatomy 0.000 abstract description 31
- 244000274050 Platycodon grandiflorum Species 0.000 abstract description 27
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 abstract description 24
- -1 anti-cancer Substances 0.000 abstract description 18
- 239000004480 active ingredient Substances 0.000 abstract description 15
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 15
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 14
- 239000003472 antidiabetic agent Substances 0.000 abstract description 12
- 235000001727 glucose Nutrition 0.000 abstract description 9
- 208000014181 Bronchial disease Diseases 0.000 abstract description 5
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 5
- 201000010881 cervical cancer Diseases 0.000 abstract description 5
- 206010038038 rectal cancer Diseases 0.000 abstract description 5
- 201000001275 rectum cancer Diseases 0.000 abstract description 5
- 241000894006 Bacteria Species 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 206010073069 Hepatic cancer Diseases 0.000 abstract description 2
- 150000002304 glucoses Chemical class 0.000 abstract description 2
- 210000003494 hepatocyte Anatomy 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 2
- 241000332371 Abutilon x hybridum Species 0.000 description 52
- 238000001035 drying Methods 0.000 description 36
- 208000035199 Tetraploidy Diseases 0.000 description 28
- 241000196324 Embryophyta Species 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 238000004108 freeze drying Methods 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000007602 hot air drying Methods 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 108060006004 Ascorbate peroxidase Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 235000006751 Platycodon Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229930189914 platycodon Natural products 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 241001249678 Klebsiella pneumoniae subsp. pneumoniae Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003028 enzyme activity measurement method Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000357613 Platycodon Species 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000004159 Potassium persulphate Substances 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241001455273 Tetrapoda Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007478 blood agar base Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940107605 borage extract Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 150000008130 triterpenoid saponins Chemical group 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 가지는 약학적 조성물에 관한 것으로서, 본 발명에 따른 조성물은 DPPH, 아질산염 또는 ABTS 양이온 소거 활성을 증가시키고, 위암세포, 유방암세포, 직장암세포, 폐암세포, 간암세포, 자궁경부암세포에서 항암활성을 보였으며, 글루코오즈 내당성이 높았고, 기관지질환의 여러 균에 항균 활성을 보임을 확인하여 항산화, 항암, 항당뇨 또는 항균 활성을 가지는 약학적 조성물로 유용하게 사용할 수 있다. 또한, 세포독성이 일어나지 않으며, 약물에 대한 독성 및 부작용도 없어 장기간 복용 시에도 안심하고 사용할 수 있으며, 체내에서도 안정한 효과가 있다.The present invention relates to a pharmaceutical composition having an antioxidant, anti-cancer, anti-diabetic or antimicrobial activity comprising an extract of Platycodon grandiflorum as an active ingredient. The composition according to the present invention increases DPPH, nitrite or ABTS cation scavenging activity, It has anticancer activity in breast cancer cells, rectal cancer cells, lung cancer cells, hepatic cancer cells and cervical cancer cells. It has high antitumor activity in glucoses, and it has antimicrobial activity against many bacteria of bronchial diseases. And can be usefully used as a pharmaceutical composition having an activity. In addition, there is no cytotoxicity, toxicity to the drug, and side effects are avoided, so that they can be used safely even when taken for a long period of time and have a stable effect in the body.
Description
본 발명은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균용 조성물에 관한 것이다. The present invention relates to a composition for antioxidant, anti-cancer, anti-diabetic or antimicrobial activity, which comprises a bellflower extract as an active ingredient.
도라지는 한의학에서는 길경(桔梗)이라고 하며, 초롱과에 속하는 다년생초로서 한국을 비롯한 중국, 일본 등지에 자생하며, 배농, 거담, 기관지염, 천식 등의 호흡기계 질환에 사용되어온 생약재이다. 또한, 도라지는 이를 이용한 한방처방 수가 동의보감에 273건, 방약합편에 49건이 수록되어 있을 정도로 다양한 약리작용을 가지고 있는데, 도라지의 주요 약리성분은 트리테르페노이드(triterpenoid)계 사포닌(saponin)이 알려져 있고, 이러한 성분은 진해, 거담작용, 중추신경억제작용(진정, 진통, 해열효과), 급만성염증에 대한 항염증 작용, 항궤양 및 위액분비 억제작용, 혈관을 확장하여 혈압을 낮추는 항콜린작용, 혈당강하작용, 콜레스테롤대사 개선작용 등이 있는 것으로 알려져 있다.Bellflower is a perennial herb that belongs to the longevity field and is native to Korea, China, and Japan. It is a medicinal herb that has been used for respiratory diseases such as drainage, germosis, bronchitis and asthma. In addition, there are various pharmacologic actions such that the number of herbal medicine using this drug is 273 in Donguibogam and 49 in amalgamation. The main pharmacological component of the phloem is triterpenoid saponin These ingredients include anticholinergic action against chlamydia, genomic action, central nervous system inhibition (sedation, analgesic, antipyretic effect), anti-inflammatory action against acute chronic inflammation, anti-ulcer and gastric secretion inhibition, anticholinergic action to lower blood pressure by expanding blood vessels, Hypoglycemic effect, and cholesterol metabolism improvement action.
이외에도 도라지의 추출물은 곰팡이의 아프라톡신을 억제하며, 이눌린 분획은 식균작용과 고형암 및 복수암에 대한 강력한 항종양 효능이 있고, 40% 도라지엑기스는 알코올 흡수 억제작용을 가지고 있다. In addition, bellflower extract inhibits fungal aprotoxin. Inulin fraction has strong antitumor activity against phagocytosis and solid and multiple cancers, and 40% bellflower extract has an alcohol absorption inhibitory action.
한편, 도라지를 포함하여 생체 유용한 생리활성물질을 함유한 식물은 1차 생산자로서 사람을 비롯한 모든 동물의 식량이 되기 때문에 이의 개량이나 증산에 대한 연구가 필요하다. On the other hand, since plants containing bioactive useful physiologically active substances, including bellflower, are the primary producers and become food for all animals including humans, it is necessary to study the improvement and the increase in production.
그 결과 식물의 세포 및 조직배양 기술이 발달하였고 미분화 세포 덩어리인 캘러스로부터 완전히 식물체의 재분화가 가능해지면서 식물자원의 효과적 활용이 가능케 되었는데, 연구 결과의 예로 식물생장조절 물질들을 사용하여 식물의 생장을 촉진시킬 수 있게 되었고, 식물의 조직이나 기관을 특수한 기내 환경 조건을 구비하여 재배함으로써 외부의 악영향을 받지 않고 기내에서 지속적인 식물 생산물을 얻을 수 있게 되었다. 이 외에도 배수체를 제조하여 식물을 증가시키는 연구도 진행되고 있다. As a result, plant cell and tissue cultivation techniques have been developed, and plant regeneration has been fully enabled from callus, which is a undifferentiated cell mass, to enable effective utilization of plant resources. As an example of the research result, plant growth regulators are used to promote plant growth And the plants organs and organs are grown with special in-cabin environmental conditions, so that continuous plant products can be obtained in the cabin without being adversely influenced by the outside. In addition, studies are underway to increase plants by producing polyploids.
한편, 개발된 종래 방법에 있어서 4배체 식물을 유도하는 방법으로는 콜히친 방법에 사용되고 있으나, 종래는 종자를 콜히친 용액에 처리하여 식물체를 획득하는 것으로 4배체의 유기 효율이 적은 단점이 있다. On the other hand, in the developed conventional method, a method of inducing tetraploid plants is used in the colchicine method, but conventionally, there is a disadvantage in that the organic efficiency of the tetraploid is low by obtaining the plant by treating the seed with colchicine solution.
또한, 기내라는 특수 환경 하의 식물 생장 증식은 여러 가지 기내 환경에 맞는 선별적인 영양분이 필요하며, 대상이 되는 식물의 종류 및 특성에 따른 적정배지가 필요한 문제점이 있다. In addition, plant propagation propagation under a special environment of a cabin requires selective nutrients suitable for various cabin environments, and there is a problem that a proper medium is required depending on the type and characteristics of plants to be treated.
이에 본 발명에서는 도라지의 생리활성물질을 극대화할 수 있는 방법을 찾기 위해 노력하였으며, 이렇게 제조된 추출물을 이용하여 항산화, 항암, 항당뇨 또는 항균 활성을 갖는 약학적 조성물을 제조하였다.Accordingly, in the present invention, efforts have been made to find a method for maximizing the physiologically active substance of Platycodon grandiflorum, and a pharmaceutical composition having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity was prepared using the extract thus prepared.
따라서 본 발명의 목적은 생체에 부작용이 없으면서 다양한 약리 효과를 갖는 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 갖는 약학적 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a pharmaceutical composition having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity, which comprises as an active ingredient, a bellflower extract having various pharmacological effects without adverse effects on living bodies.
또한, 본 발명의 목적은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 갖는 건강기능식품을 제공하는 것이다. It is also an object of the present invention to provide a health functional food having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity which comprises a bellflower extract as an active ingredient.
상기와 같은 본 발명의 목적을 달성하기 위해서, 본 발명은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 갖는 약학적 조성물을 제공한다.In order to achieve the object of the present invention as described above, the present invention provides a pharmaceutical composition having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity, which comprises Platycodon grandiflorum extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 도라지는 2배체 또는 4배체일 수 있다.In one embodiment of the present invention, the bellflower may be diploid or tetraploid.
본 발명의 일실시예에 있어서, 상기 추출물은 물, 유기용매 또는 이들의 혼합 용매 추출물일 수 있다.In one embodiment of the present invention, the extract may be water, an organic solvent or a mixed solvent extract thereof.
본 발명의 일실시예에 있어서, 상기 추출물은 동결건조, 자연건조, 열풍건조 또는 마이크로웨이브건조를 수행한 것일 수 있다.In one embodiment of the present invention, the extract may be lyophilized, naturally dried, hot air dried or microwave dried.
본 발명의 일실시예에 있어서, 상기 추출물은 DPPH, 아질산염 또는 ABTS 양이온 소거 활성을 증가시키는 것일 수 있다. In one embodiment of the present invention, the extract may be one that increases DPPH, nitrite or ABTS cation scavenging activity.
본 발명의 일실시예에 있어서, 상기 조성물은 곰보배추, 산수유 및 유자에서 선택되는 하나 이상의 첨가물을 더 포함하는 것일 수 있다. In one embodiment of the present invention, the composition may further comprise at least one additive selected from pale blue cabbage, corn oil and citron.
본 발명의 일실시예에 있어서, 상기 추출물은 직장암 또는 자궁경부암 세포 사멸 활성을 갖는 것일 수 있다.In one embodiment of the present invention, the extract may have rectal cancer or cervical cancer cell killing activity.
본 발명의 일실시예에 있어서, 상기 추출물은 디프테리아균(Corynebacterium diphtheriae) KCCM 40413, 클렙시엘라 폐렴균(Klebsiella pneumoniae subsp . pneumoniae) KCCM 41285, 화농연쇄구균(Streptococcus pyogenes) KCCM 11817으로 이루어진 군 중에서 선택되는 하나 이상의 균주를 억제하는 활성을 갖는 것일 수 있다. In one embodiment of the present invention, the extract is selected from the group consisting of Corynebacterium diphtheriae ) KCCM 40413, Klebsiella pneumoniae subsp . pneumoniae ) KCCM 41285, Streptococcus pyogenes KCCM 11817. In addition,
나아가 본 발명은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 갖는 건강기능식품을 제공한다. Further, the present invention provides a health functional food having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity, which comprises a bellflower extract as an active ingredient.
본 발명은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 가지는 약학적 조성물에 관한 것으로서, 본 발명에 따른 조성물은 DPPH, 아질산염 또는 ABTS 양이온 소거 활성을 증가시키고, 위암세포, 유방암세포, 직장암세포, 폐암세포, 간암세포, 자궁경부암세포에서 항암활성을 보였으며, 글루코오즈 내당성이 높았고, 기관지질환의 여러 균에 항균 활성을 보임을 확인하여 항산화, 항암, 항당뇨 또는 항균 활성을 가지는 약학적 조성물로 유용하게 사용할 수 있다. 또한, 세포독성이 일어나지 않으며, 약물에 대한 독성 및 부작용도 없어 장기간 복용 시에도 안심하고 사용할 수 있으며, 체내에서도 안정한 효과가 있다.The present invention relates to a pharmaceutical composition having an antioxidant, anti-cancer, anti-diabetic or antimicrobial activity comprising an extract of Platycodon grandiflorum as an active ingredient. The composition according to the present invention increases DPPH, nitrite or ABTS cation scavenging activity, It has anticancer activity in breast cancer cells, rectal cancer cells, lung cancer cells, hepatic cancer cells and cervical cancer cells. It has high antitumor activity in glucoses, and it has antimicrobial activity against many bacteria of bronchial diseases. And can be usefully used as a pharmaceutical composition having an activity. In addition, there is no cytotoxicity, toxicity to the drug, and side effects are avoided, so that they can be used safely even when taken for a long period of time and have a stable effect in the body.
도 1은 2배체, 4배체 도라지 추출물의 건조방법별 SOD효소 활성을 측정한 결과이다(FD: 동결건조, ID: 자연건조, HD: 열풍건조, MD: 마이크로웨이브 건조).
도 2는 2배체, 4배체 도라지 추출물의 건조방법별 CAT 활성을 측정한 결과이다(FD: 동결건조, ID: 자연건조, HD: 열풍건조, MD: 마이크로웨이브 건조).
도 3은 2배체, 4배체 도라지 추출물의 건조방법별 APX 활성을 측정한 결과이다(FD: 동결건조, ID: 자연건조, HD: 열풍건조, MD: 마이크로웨이브 건조).
도 4는 2배체, 4배체 도라지 추출물의 건조방법별 POD 활성을 측정한 결과이다(FD: 동결건조, ID: 자연건조, HD: 열풍건조, MD: 마이크로웨이브 건조).
도 5는 디프테리아균(Corynebacterium diphtheriae) KCCM 40413의 항균활성 정도를 측정한 결과이다(A: 2배체, B: 4배체).
도 6은 클렙시엘라 폐렴균(Klebsiella pneumoniae subsp . pneumoniae) KCCM 41285의 항균활성 정도를 측정한 결과이다(A: 2배체, B: 4배체).
도 7은 화농연쇄구균(Streptococcus pyogenes) KCCM 11817의 항균활성 정도를 측정한 결과이다(A: 2배체, B: 4배체).FIG. 1 shows the results of measurement of SOD enzyme activity of the diploid and tetraploid strained extracts (FD: freeze drying, ID: natural drying, HD: hot air drying, MD: microwave drying).
FIG. 2 shows the results of measurement of CAT activity by the drying method of diploid and tetraploid strained extract (FD: freeze drying, ID: natural drying, HD: hot air drying, MD: microwave drying).
FIG. 3 shows the results of measurement of APX activity of the diploid and tetraploid strained extracts (FD: freeze drying, ID: natural drying, HD: hot air drying, MD: microwave drying).
FIG. 4 shows the result of measurement of POD activity of the diploid and tetraploid strained extracts (FD: freeze drying, ID: natural drying, HD: hot air drying, MD: microwave drying).
Figure 5 is a graph showing the effect of the Corynebacterium diphtheriae ) KCCM 40413 (A: diploid, B: tetrad).
FIG. 6 is a graph showing the activity of Klebsiella pneumoniae subsp . pneumoniae ) KCCM 41285 (A: diploid, B: tetrad).
Figure 7 is a graph showing the effect of Streptococcus pyogenes ) KCCM 11817 (A: diploid, B: tetrad).
본 발명은 도라지 추출물을 유효성분으로 포함하는 항산화, 항암, 항당뇨 또는 항균 활성을 갖는 약학적 조성물을 제공함을 특징으로 한다.The present invention is characterized by providing a pharmaceutical composition having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity, which comprises Platycodon grandiflorum extract as an active ingredient.
‘도라지’는 한의학에서는 길경이라고도 하는데 성질은 약간 따뜻하며 독이 많고 맛은 맵고 쓰다. 한방에서 길경은 노쇠하거나 폐기가 완전히 쇠약해지지 않은 사람의 기관지와 폐의 병에 특효약이라고 언급한다. 주로 기혈을 보강해주고 뱃속의 냉기를 덜어주어 심장쇠약, 설사, 주독 등에도 효과를 나타내는데 이는 도라지의 주성분이라 할 수 있는 사포닌에 의한 것으로 거담, 항염, 항궤양, 부신피질호르몬 분비촉진, 기도점액분비, 타액분비 촉진 등의 약리작용을 나타내며 면역력을 강화시키는 영양소라고 알려져 있다. 'Doraji' is called Gyungyang in oriental medicine, but its quality is slightly warm and poisonous and its taste is spicy. In one room, Gyung-kyung refers to a disease of the bronchi and lungs of people who are not fully decayed or discarded. It is mainly due to saponin, which is the main component of the bellflower, and it can be used for the treatment of diabetes, anti-inflammation, anti-ulcer, promotion of corticosteroid secretion, airway mucus secretion , Saliva secretion and promote the action of the pharmacological effects are known to enhance nutritional power.
이에 본 발명자들은 도라지의 생리활성물질을 극대화할 수 있는 방법을 찾기 위해 노력하던 중 2배체 도라지에 비해 4배체 도라지에서 생리활성물질의 효과가 더욱 좋음을 알 수 있었으며, 건조방법에 따라서도 효과가 달라질 수 있음을 확인하였다. Therefore, the present inventors have found that the effect of the physiologically active substance is better in the quadriceps than in the diploid bellflower when trying to find a method of maximizing the physiologically active substance of the bellflower, .
본 발명의 일실시예에 따르면, 도라지 추출물을 2배체와 4배체로 나누었으며, 동결건조(FD), 실내건조(ID), 열풍건조(HD), 마이크로웨이브 건조(MD)의 방법 및 다양한 농도로 처리하여 DPPH 소거 활성을 분석한 결과, 2배체 도라지에 비해 4배체 도라지에서 DPPH 라디칼 소거능이 높게 나타났으며, 건조방법별로는 동결건조한 시료에서 비교적 높은 효능을 보였고, 이러한 DPPH 소거 활성의 증가는 농도에 비례하는 농도의존적 경향을 나타냄을 알 수 있었다(표 2 참조).According to one embodiment of the present invention, the bellflower extract is divided into a diploid and a tetraploid, and the method of freeze drying (FD), indoor drying (ID), hot air drying (HD), microwave drying (MD) , DPPH radical scavenging activity was higher than that of diploid bellflower, and the degree of DPPH radical scavenging activity was higher than that of diploid bellflower. The degree of DPPH scavenging activity was higher than that of freeze dried sample, (See Table 2).
본 발명의 일실시예에 따르면, 도라지 추출물을 2배체와 4배체로 나누었으며, 동결건조(FD), 실내건조(ID), 열풍건조(HD), 마이크로웨이브 건조(MD)의 방법 및 다양한 농도의 pH를 처리하여 도라지의 아질산염 소거능을 측정한 결과, 반응 용액이 pH 1.2일 경우 시료 추출물 대부분이 아질산염을 60% 이상 분해시킬 수 있었으며, 이 중 2배체 도라지의 자연건조와 마이크로웨이브 건조에서 각각 69.8%와 66.7%로 가장 높은 아질산염 소거 활성을 나타냈다. 2배체 도라지에서 4배체 도라지보다 상대적으로 다소 높은 소거능을 보였지만, 크게 유의성 있는 차이는 아니었다(표 4 참조).According to one embodiment of the present invention, the bellflower extract is divided into a diploid and a tetraploid, and the method of freeze drying (FD), indoor drying (ID), hot air drying (HD), microwave drying (MD) The nitrite scavenging activity of Rhodophyllum japonica was measured at pH 1.2. Most of the extracts were able to decompose more than 60% of nitrite, % And 66.7%, respectively, which showed the highest nitrite scavenging activity. In diploid bellflower, it showed relatively higher elimination than quadruple bellflower, but not significant difference (see Table 4).
본 발명의 일실시예에 따르면, ABTS 양이온 소거활성을 2배체, 4배체 도라지의 건조방법별 검증한 결과를 보면, 추출물의 농도가 증가할수록 비례적으로 증가되는 경향을 보였으며, 대체적으로 4배체 도라지에서 2배체 도라지보다 상대적으로 높은 소거활성을 나타냈지만, 건조방법은 소거활성의 변화에 그다지 영향을 주지 못함을 알 수 있었다(표 6 참조).According to one embodiment of the present invention, the ABTS cation-scavenging activity of each of the tetraploids and tetraploids was found to increase proportionally with increasing concentration of the extract, It was found that the drying method had no significant effect on the change of the scavenging activity although the dredge showed relatively higher scavenging activity than the diploid doric (see Table 6).
본 발명의 일실시예에 따르면, 도라지 추출물에 항암 활성이 있는지를 알아보기 위하여 다양한 부위의 인체암세포주에 MTT방법을 이용하여 측정한 결과, 전반적으로 4배체 도라지에서 2배체 도라지보다 좋은 효과가 있는 것으로 나타났고, 여러 세포주 중에서 특히 직장암세포인 HCT 116 Cell과 자궁경부암세포인 헬라 세포(Hela Cell)에서는 상대적으로 높은 효과를 나타냈으며, MCF-7 Cell과 Calu-6 Cell에서는 다른 암세포주와 비교하여 다소 낮은 독성도를 보였음을 알 수 있었다(표 12 참조).According to one embodiment of the present invention, in order to investigate whether or not the platycodon grandiflorum extract has anticancer activity, MTT assay was applied to human cancer cells of various sites, and as a result, it was found to be more effective than tetrapod platycodon In MCF-7 cells and Calu-6 cells, HCT 116 cells and Hela cells, which are cervical cancer cells, showed relatively higher effects than other cancer cell lines. (See Table 12).
또한, 본 발명의 일실시예에 따르면, 도라지 추출물에 항당뇨 효과가 있는지를 알아보기 위하여 2배체, 4배체로 나눈 다음 건조방법에 따른 내당성 실험을 한 결과, 2배체와 4배체 도라지 추출물 모두에서 내당성이 양호하게 나타났으며, 동결건조, 자연건조보다 열풍건조 및 마이크로웨이브 건조에서 내당성이 우수함을 알 수 있었다(표 13 참조).In addition, according to one embodiment of the present invention, in order to investigate whether or not an antidiabetic effect of Platycodon grandiflorum extract has been divided into a diploid and a tetrad, the endurance test according to the drying method was carried out. As a result, , And it was found that the resistance against frost-drying, hot-air drying and microwave drying was superior to that of natural drying (see Table 13).
나아가 본 발명자들은 도라지 추출물에 항균활성이 있는지를 알아보기 위하여 3 종류의 기관지질환 유발 세균에 대한 항균활성을 측정한 결과, 4배체 도라지 도라지 추출물이 2배체 도라지와 비교하여 상대적으로 활성이 높았으며, 특히 클렙시엘라 폐렴균(Klebsiella pneumoniae subsp . pneumoniae)에서는 현저히 높은 활성을 나타냄을 알 수 있었다(도 5 내지 7 참조).Furthermore, the present inventors measured antimicrobial activity against three types of bronchial disease-causing bacteria in order to investigate whether or not they have antimicrobial activity on Platycodon grandiflorum extract. As a result, Quaternary Platycodon grandiflorum extract was relatively active compared to Diclofened Platycodon, In particular, Klebsiella pneumoniae subsp . pneumoniae ) (see Figs. 5 to 7).
따라서 이러한 결과를 통해 본 발명자들은 본 발명의 도라지 추출물이 항산화, 항암, 항당뇨 또는 항균 활성을 가지는 약학적 조성물로 사용할 수 있다는 사실을 알 수 있었다.Accordingly, the inventors of the present invention have found that the platycodon grandiflorum extract of the present invention can be used as a pharmaceutical composition having antioxidant, anti-cancer, anti-diabetic or antimicrobial activity.
본 발명에 따른 도라지는 당업계에 공지된 추출 및 분리하는 방법을 사용하여 천연으로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된‘추출물’은 적절한 용매를 이용하여 도라지로부터 추출한 것이며, 예를 들어, 도라지의 열수추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함할 수 있다.The broodstock according to the present invention can be obtained by extracting and isolating from nature using an extraction and separation method known in the art, and the 'extract' defined in the present invention is extracted from bellflower using an appropriate solvent For example, hot water extracts of bellflower, polar solvent-soluble extracts, or non-polar solvent-soluble extracts.
도라지로부터 추출물을 추출하기 위한 적절한 용매로는 당업계에서 허용되는 용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있다. 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산(cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있으나, 이에 제한되지는 않는다.As a suitable solvent for extracting the extract from the bellflower, any solvent acceptable in the art may be used, and water or an organic solvent may be used. Examples of the solvent include alcohols having 1 to 4 carbon atoms, acetone, ether, and the like, including purified water, methanol, ethanol, propanol, isopropanol, butanol, Various solvents such as benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination. But is not limited to.
추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. 본 발명의 도라지 추출물의 제조방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있다.As the extraction method, any one of the methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method and compression method can be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method. There is no limitation on the production method of the Platycodon grandiflorum extract of the present invention, and any known method can be used.
예를 들면, 본 발명의 조성물에 포함되는 도라지 추출물은 상기한 열수 추출 또는 용매 추출법으로 추출된 1차 추출물을, 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조할 수 있다. 또한 상기 1차 추출물을 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획을 얻을 수도 있다.For example, the Platycodon grandiflorum extract contained in the composition of the present invention can be prepared into a powdery state by an additional process such as vacuum distillation, freeze drying, spray drying, or the like, with the primary extract extracted by the hot water extraction or solvent extraction method described above . Further, the primary extract can be further purified by using various chromatographies such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and the like, You can get it.
따라서 본 발명에 있어서 도라지 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다.Therefore, in the present invention, the bellflower extract is a concept including all extracts, fractions, and purified products obtained in each step of extraction, fractionation, or purification, and diluted solutions, concentrates, or dried products thereof.
이러한 도라지 추출물을 유효성분으로 포함하는 본 발명의 조성물은 약제학적 조성물일 수 있다.The composition of the present invention containing such a bellflower extract as an active ingredient may be a pharmaceutical composition.
본 발명의 약제학적 조성물은 상기 유효성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
상기 약제학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 일실시예에 있어서, 본 발명의 도라지 추출물은 조성물 총 중량에 대하여 0.1ug/ml 내지 500ug/ml의 농도로 포함될 수 있다.In one embodiment of the present invention, the platycodon grandiflorum extract of the present invention may be contained at a concentration of 0.1 ug / ml to 500 ug / ml based on the total weight of the composition.
또한, 본 발명의 조성물은 또한 식품 조성물일 수 있는데, 이러한 식품 조성물은 유효성분인 도라지 추출물을 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. The composition of the present invention may also be a food composition. The food composition may contain, as an additional component, an active ingredient, a bellflower extract, as well as various flavors or natural carbohydrates, .
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제 (타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. The above-described flavors can be advantageously used as natural flavorings (tau martin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.).
본 발명의 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.The food composition of the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a food or food. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolates, foods, confectionery, pizza, ram noodles, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, .
또한 상기 식품 조성물은 유효성분인 도라지 추출물 외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. In addition, the food composition may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (such as cheese and chocolate), pectic acid and its salts , Alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
본 발명의 유효성분인 도라지 추출물은 천연물질로서 독성 및 부작용은 거의 없으므로 항산화, 항암, 항당뇨 및 항균 효과를 위한 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다.The bellflower extract of the present invention is a natural substance and has little toxicity and side effects. Therefore, it can be safely used for long-term administration for antioxidant, anti-cancer, anti-diabetic and antimicrobial effects.
본 발명의 건강기능식품은 항산화, 항암, 항당뇨 및 항균 효과를 위한 목적으로 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles for the purpose of antioxidation, anti-cancer, anti-diabetic and antimicrobial effects.
본 발명에서 “건강기능식품”이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, the term " health functional food " refers to foods manufactured and processed using raw materials or ingredients having useful functions in accordance with Law No. 6727 on Health Functional Foods. Or to obtain a beneficial effect in health use such as physiological action.
본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional foods of the present invention may contain conventional food additives and, unless otherwise specified, whether or not they are suitable as food additives are classified according to the General Rules for Food Additives approved by the Food and Drug Administration, Standards and standards.
상기 “식품 첨가물 공전”에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다.Examples of the items listed in the above-mentioned "food additives" include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as persimmon extract, licorice extract, crystalline cellulose, high color pigment and guar gum; L-glutamic acid sodium preparations, noodle-added alkalis, preservative preparations, tar coloring preparations and the like.
예를 들어, 정제 형태의 건강기능식품은 본 발명의 유효성분인 도라지 추출물을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다.For example, the health functional food in the form of tablets can be obtained by granulating a mixture obtained by mixing the active ingredient of the present invention, the bellflower extract, with an excipient, a binder, a disintegrant and other additives in a usual manner, Alternatively, the mixture can be directly compression molded. In addition, the health functional food of the tablet form may contain a mating agent or the like if necessary.
캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분인 도라지 추출물을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 도라지 추출물을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.The hard capsule of the capsule-type health functional food can be prepared by filling a common hard capsule with a mixture of an effective ingredient of the present invention, such as a bellflower extract, with an additive such as an excipient, and the soft capsule is prepared by adding a bellflower extract as an excipient And filling the mixture with a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.
환 형태의 건강기능식품은 본 발명의 유효성분인 도라지 추출물과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다.The ring-shaped health functional food can be prepared by molding a mixture of a borage extract, which is an effective ingredient of the present invention, an excipient, a binder, a disintegrant, and the like, by a conventionally known method and, if necessary, Or the surface may be coated with a material such as starch, talc.
과립 형태의 건강기능식품은 본 발명의 유효성분인 도라지 추출물과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The granular health functional food may be prepared by granulating the mixture of the active ingredient of the present invention, the granule extract, the excipient, the binder and the disintegrant in a granular form by a known method. If necessary, a flavoring agent, ≪ / RTI >
상기 건강기능식품은 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등일 수 있다.The health functional food may be a beverage, a meat, a chocolate, a food, a confectionery, a pizza, a ramen, a noodle, a gum, a candy, an ice cream, an alcoholic beverage, a vitamin complex and a health supplement food.
이하, 실시예를 통하여 본 발명을 추가적으로 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be further described by way of examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited to these examples.
<< 실시예Example 1> 1>
도라지 추출물의 제조Preparation of bellflower extract
도라지 추출물을 제조하기 위하여 본 발명자들은 도라지를 동결건조 후, 증류수와 주정알코올을 50%:50%의 비율로 3회 상온 추출한 다음 감압농축하였으며, 상기의 방법으로 감압농축된 추출물을 동결건조하여 분말화하였다. 동결건조 분말 100g을 n-헥산(n-hexane), 메틸렌 클로라이드(Methylene chloride), 아세트산에틸(Ethyl acetate), 부틸 알코올(Butyl alcohol), 증류수(D.W.) 등의 용매를 사용하여 순차적으로 연속 추출하여 분획화한 다음, 추출액을 감압농축기로 완전히 농축한 후에 무게를 측정하는 방법으로 각 분획물의 회수율을 조사하였다. In order to prepare a bellflower extract, the present inventors frozen and dried the bellflower, and extracted three times at a ratio of 50%: 50% of distilled water and alcohol at a room temperature. The extract was concentrated under reduced pressure, . A lyophilized powder 100g n - using a solvent such as hexane (n -hexane), methylene chloride (Methylene chloride), AcOEt (Ethyl acetate), butyl alcohol (Butyl alcohol), distilled water (DW) were sequentially extracted continuously After fractionation, the extract was completely concentrated with a vacuum concentrator, and the recovery of each fraction was examined by measuring the weight.
그 결과, 2배체, 4배체 도라지 모두 물 추출에서 가장 높은 회수율을 보였고 아세트산에틸 층에서는 극히 미미한 수준의 수율을 보임을 알 수 있었다(표 1 참조).
As a result, it was found that both of the diploid and tetraploid donor showed the highest recovery rate in water extraction and the yield was extremely small in the ethyl acetate layer (see Table 1).
<< 실시예Example 2> 2>
도라지 추출물의 Bellflower extract
DPPHDPPH
라디칼Radical
소거능Scatters
측정 Measure
<2-1> <2-1> 건조 방법에 따른 Depending on the drying method 2배체Diploid , , 4배체Tetraploid 도라지의 Bellflower DPPHDPPH 소거 활성 측정 Measurement of scavenging activity
본 발명자들은 실시예 1의 방법으로 제조된 도라지 추출물에 항산화 효과가 있는지 알아보기 위하여 Choi 등(2003)의 방법을 이용하여 DPPH 라디칼 소거능을 측정하였다. The present inventors measured the DPPH radical scavenging ability using the method of Choi et al. (2003) in order to investigate whether or not the borax extract prepared by the method of Example 1 had antioxidative effect.
먼저, 여러 농도의 시료를 메탄올 용매로 용해하여 900 μL의 DPPH 용액(100 μM)과 각 시료 100 μL를 혼합하여 교반하였다. 이 혼합 시료를 암소에서 30분간 반응시킨 후 517 nm에서 흡광도를 측정하였으며, 수소전자공여능은 각 실험을 3회 반복하여 평균을 낸 다음 대조구에 대한 흡광도의 감소 정도를 다음 식에 의하여 계산하였다. First, samples of various concentrations were dissolved in a methanol solvent, and 900 μL of DPPH solution (100 μM) and 100 μL of each sample were mixed and stirred. After incubation in the dark for 30 minutes, the absorbance of the mixture was measured at 517 nm. The hydrogen electron donating ability was calculated by repeating each experiment three times, and the absorbance of the control was calculated by the following equation.
An= (A0-A)/A0 × 100An = (A 0 -A) /
An : DPPH radical 소거능에 대한 항산화 활성(%)An: Antioxidant activity against DPPH radical scavenging activity (%)
A0 : 시료가 첨가되지 않은 DPPH 용액의 흡광도A 0 : Absorbance of DPPH solution without added sample
A : 반응용액 중의 DPPH와 시료의 반응한 흡광도
A: The absorbance of DPPH in the reaction solution and the absorbance of the sample
본 발명의 도라지 추출물을 2배체와 4배체로 나누었으며, 동결건조(FD), 실내건조(ID), 열풍건조(HD), 마이크로웨이브 건조(MD)의 방법 및 다양한 농도로 처리하여 DPPH 소거 활성을 분석한 결과, 2배체 도라지에 비해 4배체 도라지에서 DPPH 라디칼 소거능이 높게 나타났으며, 건조방법별로는 동결건조한 시료에서 비교적 높은 효능을 보였고, 이러한 DPPH 소거 활성의 증가는 농도에 비례하는 농도의존적 경향을 나타냄을 알 수 있었다(표 2 참조).
Platycodon grandiflorum extract of the present invention was divided into diploid and tetraploid and treated by various methods such as freeze drying (FD), indoor drying (ID), hot air drying (HD), microwave drying (MD) , DPPH radical scavenging activity was higher in the tetraploid morcellation than in the diploid bellflower. The degree of DPPH radical scavenging activity was higher in the freeze dried samples than in the other drying methods. The increase in the DPPH scavenging activity was dependent on the concentration (See Table 2).
<2-2> <2-2> 기능성 강화를 위한 선발 소재의 Selection of materials for functional enhancement DPPHDPPH 소거 활성 측정 Measurement of scavenging activity
본 발명자들은 본 발명의 도라지 추출물과 더불어 다른 식물 소재를 추가하여 더욱 더 항산화 기능이 향상된 추출물을 제조하기 위하여 다양한 식물 소재의 DPPH 소거 활성을 측정하였다. The present inventors measured the DPPH scavenging activity of various plant materials in order to further prepare antioxidant-enhanced extracts by adding other plant materials in addition to the platycodon grandiflorum extract of the present invention.
그 결과, 다양한 식물 소재에서 DPPH 소거 활성이 존재하였지만 특히 산수유와 뱀차조기 추출물에서 월등한 DPPH 소거 활성이 나타났으며, 이러한 효과는 농도의존적으로 증가함을 알 수 있었다(표 3 참조).As a result, DPPH scavenging activity was observed in various plant materials. However, DPPH scavenging activity was remarkably enhanced in the extracts of corn syrup and snakeskin, and this effect was increased in a concentration-dependent manner (see Table 3).
<< 실시예Example 3> 3>
도라지 추출물의 아질산염 Nitrite of bellflower extract
소거능Scatters
측정 Measure
<3-1> <3-1> 건조 방법에 따른 Depending on the drying method 2배체Diploid , , 4배체Tetraploid 도라지의 아질산염 Nitrite of bellflower 소거능Scatters 측정 Measure
본 발명자들은 도라지 추출물의 아질산염 소거능을 측정하기 위하여 1mM NaNO2 20㎕에 시료의 추출액 40㎕와 0.1N HCl(pH 1.2) 또는 0.2M 시트레이트 버퍼(citrate buffer (pH 4.2, 6.0))를 140㎕ 사용하여 부피를 200㎕로 맞추었다. 이 반응액을 37℃ 항온수조에서 1시간 반응시킨 후 2% 아세트산 1000㎕, Griess 시약 (30% 아세트산으로 조제한 1% 설파닐산(sulfanilic acid)과 1% 나프틸아민(naphthylamine)을 1:1 비율로 혼합한 것, 사용직전에 조제) 80㎕를 가하여 잘 혼합시켜 빛을 차단한 상온에서 15분간 반응시킨 후 520nm에서 흡광도를 측정하여 아래와 같이 아질산염 소거능을 구하였다. To measure the nitrite scavenging ability of Platycodon grandiflorum extract, 140 μl of a sample extract and 40 μl of 0.1 N HCl (pH 1.2) or 0.2 M citrate buffer (citrate buffer (pH 4.2, 6.0)) were added to 20 μl of 1 mM NaNO 2 And the volume was adjusted to 200 μl. The reaction solution was reacted in a constant temperature water bath at 37 ° C for 1 hour, and then 1000 μl of 2% acetic acid and 1% of a Griess reagent (1% sulfanilic acid and 1% naphthylamine prepared by 30% acetic acid) , Prepared immediately before use), and the mixture was well mixed. The mixture was reacted at room temperature for 15 minutes with blocking of light, and the absorbance at 520 nm was measured to determine the nitrite scavenging ability as follows.
N(%) = [1-(A-C)/B]×100 N (%) = [1- (A-C) / B] 100
N : 아질산염소거(nitrite scavenging ability) N: nitrite scavenging ability
A : 1시간 기다린 후 샘플에 1mM 아질산염을 가한 다음의 흡광도(absorbance of 1mM NaNO2 added sample after standing for 1hour)A: Add 1 mM nitrite to the sample after waiting 1 hour, and then add absorbance of 1 mM NaNO 2 added after standing for 1 hour.
B : 아질산염의 흡광도(absorbance of 1NaNO2)B: Absorbance of nitrite (absorbance of 1NaNO 2 )
C : 대조군의 흡광도(absorbance of control)
C: absorbance of control (control)
본 발명의 도라지 추출물을 2배체와 4배체로 나누었으며, 동결건조(FD), 실내건조(ID), 열풍건조(HD), 마이크로웨이브 건조(MD)의 방법 및 다양한 pH를 처리하여 도라지의 아질산염 소거능을 측정한 결과, 반응 용액이 pH 1.2일 경우 시료 추출물 대부분이 아질산염을 60% 이상 분해시킬 수 있었으며, 이 중 2배체 도라지의 자연건조와 마이크로웨이브 건조에서 각각 69.8%와 66.7%로 가장 높은 아질산염 소거 활성을 나타냈다. 2배체 도라지에서 4배체 도라지보다 상대적으로 다소 높은 소거능을 보였지만, 크게 유의성 있는 차이는 아니었다. pH 4.2에서도 대부분 50% 이상의 아질산염 소거활성을 나타냈지만, pH 6.0에서는 거의 대부분 활성이 없었다. The Platycodon grandiflorum extract of the present invention was divided into diploid and tetraploid and treated with various methods such as freeze drying (FD), indoor drying (ID), hot air drying (HD), microwave drying (MD) When the reaction solution was pH 1.2, most of the extracts could decompose more than 60% of the nitrite. Among them, the highest degree of nitrite (69.8% and 66.7% Respectively. In diploid bellflower, it was relatively higher than quadruple bellflower, but it was not significantly different. At pH 4.2, most of the nitrite scavenging activity was more than 50%, but almost no activity was observed at pH 6.0.
따라서 pH 변화에 따른 식물 배수성별, 건조방법별 추출물의 아질산염 소거활성은 pH 1.2에서 가장 높았으며 pH가 증가함에 따라 활성도 점차 감소되거나 상실되었음을 알 수 있었다.
Therefore, the nitrite scavenging activity of the extracts of each plant by drainage method and drying method was the highest at pH 1.2 and the activity gradually decreased or decreased with increasing pH.
<3-2> <3-2> 기능성 강화를 위한 선발 소재의 아질산염 Nitrite of choice material for functional enhancement 소거능Scatters 측정 Measure
본 발명자들은 본 발명의 도라지 추출물과 더불어 다른 식물 소재를 추가하여 더욱 더 항산화 기능이 향상된 추출물을 제조하기 위하여 다양한 식물 소재의 pH농도를 달리하여 아질산염 소거능을 측정하였다.
The present inventors measured the nitrite scavenging ability by varying the pH concentration of various plant materials in order to further prepare an extract having improved antioxidative function by adding other plant materials in addition to the plant extract of the present invention.
그 결과, 반응 용액이 pH 1.2일 경우 시료 추출물 대부분이 아질산염을 85% 이상 분해시킬 수 있었으며, pH 4.2에서도 대부분 10% 이상의 아질산염 소거활성을 나타냈지만, pH 6.0에서는 거의 대부분 활성이 없었다. As a result, most of the sample extracts could decompose more than 85% of the nitrite when the reaction solution was pH 1.2, and the nitrite scavenging activity was more than 10% at pH 4.2, but almost no activity at pH 6.0.
따라서 pH 변화에 따른 추출물의 아질산염 소거활성은 pH 1.2에서 가장 높았으며 pH가 증가함에 따라 활성도 점차 감소되거나 상실되었음을 알 수 있었고, 다양한 식물 소재 중 산수유 및 여주 추출물에서 월등한 아질산염 소거활성을 보임을 알 수 있었다(표 5 참조).
Therefore, the nitrite scavenging activity of the extracts was the highest at pH 1.2, and the activity was gradually decreased or lost as the pH was increased. The nitrite scavenging activity of the extracts of Sansui and Yeoju (See Table 5).
<< 실시예Example 4> 4>
도라지 추출물의 Bellflower extract
ABTSABTS
양이온( Cation (
ABTSABTS
+) 소거활성 측정+) Measurement of scavenging activity
<4-1> <4-1> 건조 방법에 따른 Depending on the drying method 2배체Diploid , , 4배체Tetraploid 도라지의 Bellflower ABTSABTS 양이온 소거활성 측정 Measurement of cation-scavenging activity
본 발명자들은 도라지 추출물의 ABTS 양이온 소거활성을 측정하기 위하여 7.4 mM ABTS(2,2'-azinbis-(3-ethyl-benzothiazoline-6-sulfonic acid) 용액과 2.6 The present inventors measured ABTS cation scavenging activity of Platycodon grandiflorum extract by using 7.4 mM ABTS (2,2'-azinbis- (3-ethyl-benzothiazoline-6-sulfonic acid)
mM과 황산칼륨(potassium persulphate)을 혼합한 다음 암소에서 약 15시간 반응시킨 후 414 nm에서 흡광도가 1.5가 되도록 희석하였다.mM and potassium persulphate were mixed and reacted in a dark place for about 15 hours. Then, the mixture was diluted to a absorbance of 1.5 at 414 nm.
희석한 용액 3 ㎖에 각 농도별로 조제한 시료 150 ㎕를 첨가한 다음 시험관 혼합기(vortex mixer)로 10초간 진탕하고 실온에 90분간 방치한 후 414 nm에서 흡광도를 측정하였다. 한편, 아스코르브산(ascorbic acid)을 시료와 같은 농도로 조제하여 동일한 방법으로 흡광도를 측정함으로써 비교하였다. 150 μl of each sample was added to 3 ml of the diluted solution. The sample was shaken for 10 seconds in a vortex mixer, left at room temperature for 90 minutes, and then absorbed at 414 nm. On the other hand, ascorbic acid was prepared at the same concentration as the sample and the absorbance was measured by the same method.
양이온 소거능은 AEAC(relative ascorbic acid equivalent antioxidant capacity)로 나타내었으며, 이는 아스코르브산의 소거능을 1.000으로 하였을 때 동일농도 시료의 ABTS 양이온 소거능을 나타내는 것으로 다음과 같은 식에 의해 계산하였다.The cationic scavenging activity was expressed as AEAC (relative ascorbic acid equivalent antioxidant capacity), which indicates the ABTS cation elimination activity of the same concentration sample when the scavenging activity of ascorbic acid is 1.000.
RAEAC = Caa × △ As RAEAC = Caa × △ As
△Aaa Cs Aaa Cs
ΔAaa : 아스코르브산 넣었을 때 흡광도 변화, Caa : 아스코르브산의 농도 ΔAaa: Absorbance change when ascorbic acid is added, Caa: Concentration of ascorbic acid
ΔAs : 시료 넣었을 때 흡광도 변화, Cs : 시료 농도
ΔAs: Absorbance change when sample is loaded, Cs: Sample concentration
ABTS 양이온 소거활성을 2배체, 4배체 도라지의 건조방법별 검증한 결과를 보면, 추출물의 농도가 증가할수록 비례적으로 증가되는 경향을 보였으며, 대체적으로 4배체 도라지에서 2배체 도라지보다 상대적으로 높은 소거활성을 나타냈지만, 건조방법은 소거활성의 변화에 그다지 영향을 주지 못함을 알 수 있었다(표 6 참조).
The ABTS cation-scavenging activity of the tetraploid bellflower showed a tendency to increase proportionally with the increase of the concentration of the extract. In general, the tetraploid bellflower exhibited a relatively higher (See Table 6). However, it was found that the drying method had little effect on the change of the scavenging activity (see Table 6).
<4-2> <4-2> 기능성 강화를 위한 선발 소재의 Selection of materials for functional enhancement ABTSABTS 양이온 소거활성 측정 Measurement of cation-scavenging activity
본 발명자들은 본 발명의 도라지 추출물과 더불어 다른 식물 소재를 추가하여 보다 더 항산화 기능이 향상된 추출물을 제조하기 위하여 다양한 식물 소재의 농도를 달리하여 ABTS 양이온 소거활성을 측정하였다. The present inventors measured the ABTS cation scavenging activity by varying the concentration of various plant materials in order to produce an extract having improved antioxidative function by adding other plant materials in addition to the plant extract of the present invention.
그 결과, 다양한 식물 소재에서 ABTS 양이온 소거활성이 존재하였지만 특히 산수유, 뱀차조기 및 유자(과피 또는 잎) 추출물에서 월등한 ABTS 양이온 소거활성을 보였으며, 이러한 효과는 농도의존적으로 증가함을 알 수 있었다(표 7 참조).As a result, ABTS cation-scavenging activity was present in various plant materials, but ABTS cation-scavenging activity was particularly remarkable in corn oil, snakeskin and citrus (pea or leaf) extracts, and this effect was increased in a concentration-dependent manner (See Table 7).
기능성 강화 소재로서 선발된 8종의 식물을 대상으로 항산화활성을 검증한 결과를 보면, DPPH소거능, 아질산염 소거능, ABTS 소거능 결과 모두에서 곰보배추, 산수유, 유자가 다른 식물보다 상대적으로 높게 나타났으며, 따라서 도라지 소재 외 첨가소재로서는 이들 식물이 적합하다.
The DPPH scavenging ability, nitrite scavenging ability and ABTS scavenging ability of the eight plants selected as the functional reinforcing materials were found to be higher than those of other plants. Therefore, these plants are suitable as the materials other than the bellflower.
<< 실시예Example 5> 5>
도라지 추출물의 건조방법별 항산화효소 활성 측정Determination of Antioxidant Enzyme Activity by Drying Method of Bellflower Extract
<5-1> <5-1> SODSOD ( ( SuperOxideSuperOxide DismutaseDismutase ) 효소활성 측정) Enzyme activity measurement
시료 0.5g에 분획 버퍼(extraction buffer)[100 mM K-PO4 buffer(pH7.5), 100 mM EDTA, 1% PVP, 100 mM PMSF] 2 ml로 균질화하여 15,000g 로 20분간 원심분리한 다음 상층액을 항산화활성 측정에 사용하였다. Ascorbate peroxidase(APX)의 경우 분획 버퍼(extraction buffer)에 위의 조성액 10mM를 첨가하여 사용하였다. 단백질 정량은 BSA를 표준물질로 사용하여 Bradford (1976)방법에 따라 측정하였으며, SOD효소 활성 검정은 분석용 Kit (Sigma사,19160)를 사용하여 측정하였다. 즉, SOD의 효소활성이 NBT(Nitroblue tetrazolium)의 환원을 저해하는 능력을 검정하는 photochemical NBT method를 사용하였다. 반응액은 50 mM 카르보닉 버퍼(carbonic buffer, pH 10.2), 0.1 mM EDTA, 0.1 mM 크산틴(Xanthine), 0.025 mM NBT로 하였으며, NBT환원 저해율을 흡광도 450nm에서 측정하였다. 각 시료에 대하여 3회 반복으로 하였으며, SOD효소 활성은 다음의 계산식에 의해 환산하였다.To 0.5 g of the sample was added an extraction buffer [100 mM K-PO 4 (pH 7.5), 100 mM EDTA, 1% PVP, 100 mM PMSF] and centrifuged at 15,000 g for 20 min. The supernatant was used for antioxidant activity assay. Ascorbate peroxidase (APX) was prepared by adding 10 mM of the above composition to an extraction buffer. Protein quantification was performed using Bradford (1976) method using BSA as a standard and SOD enzyme activity assay was performed using an assay kit (Sigma, 19160). That is, the photochemical NBT method was used to test the ability of SOD enzyme to inhibit the reduction of NBT (Nitroblue tetrazolium). The reaction mixture was adjusted to 50 mM carbonic buffer (pH 10.2), 0.1 mM EDTA, 0.1 mM xanthine and 0.025 mM NBT, and the inhibition of NBT reduction was measured at 450 nm. Each sample was repeated 3 times, and SOD enzyme activity was calculated by the following equation.
SOD활성 (NBT환원 저해율, %) = {[(Ablank1-Ablank3)-(Asample-Ablank2)] / (Ablank1-Ablank3)x100SOD activity (NBT reduction inhibition rate,%) = {[(A blank1 -A blank3 ) - (A sample -A blank2 )] / (A blank1 -A blank3 )
그 결과, 동결건조 및 자연건조한 4배체 도라지에서 90%로 가장 높은 활성을 보인 반면, 마이크로웨이브 건조의 2배체 도라지에서 47.5%로 가장 낮은 활성을 나타내었으며, 전체적으로 4배체 도라지가 2배체 도라지보다 상대적으로 다소 높은 활성을 보였다(도 1 참조).
As a result, the highest activity was shown to be 90% in the freeze-dried and naturally dried quadriporadia, while the lowest activity was found in microwave dried dodecahontrate, which was the lowest in 47.5% (See Fig. 1).
<5-2> <5-2> CATCAT (( CatalaseCatalase ) 활성 측정) Active measurement
CAT활성은 Aebi 등(1984)의 방법에 의해 측정하였으며, 반응액은 50 mM 포타슘 포스페이트 버퍼(potassium phosphate buffer, pH 7.0)와 10 mM H2O2로 하였다. CAT 활성은 반응액에 추출액을 가한 다음 240 mM에 2분간의 흡광도 변화를 측정하였다. CAT activity was measured by the method of Aebi et al. (1984). The reaction solution was 50 mM potassium phosphate buffer (pH 7.0) and 10 mM H 2 O 2 . CAT activity was measured by adding the extract to the reaction solution and then changing the absorbance at 240 mM for 2 minutes.
그 결과, 모든 건조조건에서 4배체 도라지의 활성이 2배체에서 보다 높은 결과를 보였다. 건조방법은 동결건조와 자연건조에서 상대적으로 높은 활성을 나타냈다(도 2 참조).As a result, the activity of tetraploid bellflower was higher in diploids than in all other drying conditions. The drying method showed relatively high activity in freeze drying and natural drying (see FIG. 2).
<5-3> <5-3> APXAPX ( ( AscorbateAscorbate PeroxidasePeroxidase ) 활성 측정) Active measurement
APX 활성은 Nacano and Asada(1981)방법에 따라 아스코르브산염(ascorbate)의 산화 정도를 290nm에서 2분간의 흡광도 변화를 측정하였다. APX의 반응액은 0.5mM 아스코르브산염와 0.2mM H2O2가 첨가된100mM 포타슘 포스페이트 버퍼(potassium phosphate buffer, pH 7.5)로 하였다.The APX activity was measured by the Nacano and Asada (1981) method. The degree of oxidation of ascorbate was measured at 290 nm for 2 minutes. The reaction solution of APX was made with 100 mM potassium phosphate buffer (pH 7.5) containing 0.5 mM ascorbate and 0.2 mM H 2 O 2 .
그 결과, 동결건조한 도라지에서 다소 높은 활성을 보였지만, 배수성과 건조방법 간에 유의성있는 차이를 나타내지는 않았다(도 3 참조).
As a result, although slightly higher activity was observed in lyophilized bellflower, there was no significant difference between drainage and drying method (see FIG. 3).
<5-4><5-4> POXPOX ( ( PeroxidasePeroxidase ) 활성 측정) Active measurement
POX활성은 Egley 등 (1983)의 방법에 의해 측정하였으며, 반응액은 최종농도가 40mM K-PO4 buffer (pH6.9), 1.5mM guaiacol, 6.5mM H2O2가 되도록 만든다. POD 활성은 반응액에 샘플을 혼합하여 스펙트로포타미터(spectrophotometer)를 이용해서 470nm에서 2분간 흡광도 변화를 측정하였다.POX activity was measured by the method of Egley et al. (1983), and the reaction solution had a final concentration of 40 mM K-PO 4 buffer (pH 6.9), 1.5 mM guaiacol, and 6.5 mM H 2 O 2 . The POD activity was measured by measuring the absorbance change at 470 nm for 2 minutes using a spectrophotometer by mixing the sample into the reaction solution.
그 결과, 2배체, 4배체 도라지 모두 동결건조 및 자연건조에서 상대적으로 높은 활성을 보였지만, 배수성 간에는 유의한 차이를 나타내지 않았다(도 4 참조).
As a result, both diploid and tetraploid gypsophila showed relatively high activity in freeze drying and natural drying, but did not show any significant difference between the palatability (see FIG. 4).
<< 실시예Example 6> 6>
도라지 추출물의 Bellflower extract 용매분획별By solvent fraction 항산화효소 활성 측정 Antioxidant enzyme activity measurement
각 시료 추출물의 용매분획별 항산화효소 활성을 보면, SOD와 CAT 활성은 에틸아세테이트(Ethyl acetate)분획과 메틸렌 클로라이드(Methylene chloride) 분획에서, APX 활성은 부틸알코올(Butyl alcohol) 분획과 물(Water) 분획에서, 그리고 POD 활성은 메틸렌 클로라이드 분획과 물 분획에서 상대적으로 높은 활성을 보였다. 전반적으로 4배체 도라지가 2배체 도라지에서보다 활성이 높은 것을 알 수 있었다(표 8 내지 11 참조).
The SOD and CAT activities of the extracts were determined by ethyl acetate fraction and methylene chloride fraction, APX activity by Butyl alcohol fraction and water fraction, In the fraction, POD activity showed relatively high activity in methylene chloride fraction and water fraction. Overall, it was found that the quadriceps dandelion was more active than the dodecane bellflower (see Tables 8-11).
<< 실시예Example 7> 7>
도라지 추출물의 항암활성 분석Analysis of Anticancer Activity of Platycodon grandiflorum Extract
본 발명자들은 도라지 추출물에 항암 활성이 있는지를 알아보기 위하여 2배체, 4배체 도라지를 준비하였으며 MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5- diphenyltetrazoliumbromide) 분석을 실시하여 측정하였다. The present inventors prepared tetraploid and tetraploid Dorrhiza to investigate the anticancer activity of Platycodon grandiflorum extract and analyzed MTT (3- (4,5-dimethyl-thiazol-2-yl) -2,5- diphenyltetrazoliumbromide) Respectively.
위암세포인 SNU-601, SNU-1066, 유방암세포인 MCF-7, 직장암세포인 HCT-116, 폐암세포인 Calu-6, 간암세포인 Hep 3B, 자궁경부암세포인 Hela 등 7종의 세포를 96웰 플레이트에 분주하고 37℃, 5%, CO2 인큐베이터에서 24시간 동안 배양하였다.Seven types of cells, including SNU-601, SNU-1066, MCF-7 breast cancer cell, HCT-116 rectal cancer cell, Calu-6 lung cancer cell, Hep 3B hepatocarcinoma cell, Hela cell cervical cancer cell, Well plate, and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours.
배양한 세포에 시료 농도가 125, 250, 500, 1000, 2000, 4000㎍/㎖이 되도록 10㎕ 처리한 후, 각각 24시간 배양하였고, 0.2㎎/㎖의 MTT 용액 10㎕를 각 웰에 넣고 인큐베이터에서 4시간 동안 배양하였다. 배양 종료 후 상등액을 제거하고 각 웰에 100㎕의 DMSO를 첨가하여 상온에서 10분 동안 반응시킨 후 흡광기(microplate reader)로 540nm에서 흡광도를 측정하였고, 세포독성은 시료의 흡광도를 대조군의 흡광도에 대한 백분율로 나타내었다.
The cultured cells were treated with 10 μl of each sample to a concentration of 125, 250, 500, 1000, 2000, and 4000 μg / ml, and cultured for 24 hours. 10 μl of 0.2 mg / ml MTT solution was added to each well, For 4 hours. After the incubation, the supernatant was removed, and 100 μl of DMSO was added to each well. The mixture was reacted at room temperature for 10 minutes, and the absorbance was measured at 540 nm using a microplate reader. The cytotoxicity was measured by the absorbance of the sample As a percentage.
MTT방법에 의한 각 시료 추출물의 인체암세포주에 대한 세포독성도를 확인한 결과, 전반적으로 4배체 도라지에서 2배체 도라지보다 좋은 효과가 있는 것으로 나타났다. 특히 직장암세포인 HCT 116 Cell과 자궁경부암세포인 헬라 세포(Hela Cell)에서는 상대적으로 높은 효과를 나타냈으며, MCF-7 Cell과 Calu-6 Cell에서는 다른 암세포주와 비교하여 다소 낮은 독성도를 보였음을 알 수 있었다(표 12 참조).
The cytotoxicity of each sample extract by MTT method to human cancer cell lines was found to be better than that of diploid bellflower in tetrads. In particular, HCT 116 cells and Hela Cells, which are rectal cancer cells and Hela Cells, showed relatively high toxicity, while MCF-7 and Calu-6 Cells showed slightly lower toxicity than the other cancer cell lines (See Table 12).
<< 실시예Example 8> 8>
도라지 추출물의 Bellflower extract 항당뇨활성Antidiabetic activity 분석 analysis
또한, 본 발명자들은 도라지 추출물에 항당뇨 효과가 있는지를 알아보기 위하여 내당성 실험을 수행하였다.In addition, the present inventors conducted an endurance test to see whether or not the bellflower extract had an anti-diabetic effect.
내당성(glucose tolerance test) 실험은 글루코오즈(Glucose) 함량을 측정하는 방법에 의해 수행하였으며, 본 발명자들은 각 시료 추출액이 글루코오즈 함량에 미치는 효과를 측정하고자 BCS 글루코오즈 키트를 사용하여 분석하였다. 효소시약을 완충용액에 용해시킨 효소액 1.5 ml에 각 식물 추출액 10 μl을 넣고 충분히 혼합하여 37℃에서 5분간 가온한 후 40분 이내에 blank를 대조로 하여 파장 505 nm에서 흡광도를 측정하였으며 다음의 식에 따라 글루코오즈 함량을 측정하였다. 이때, 효소액 1.5 ml에 표준액 (glucose 200mg/dl) 20ul를 넣은 용액을 표준용액으로 사용하였다.The glucose tolerance test was carried out by measuring the glucose content. The inventors used the BCS glucoose kit to analyze the effect of each sample extract on the glucoside content. 10 μl of each plant extract was added to 1.5 ml of the enzyme solution dissolved in the buffer solution, mixed thoroughly, heated at 37 ° C for 5 minutes, and absorbance was measured at a wavelength of 505 nm within 40 minutes by blank control. And then the glucose content was measured. At this time, 20 ml of the standard solution (
글루코오즈 함량 (mg/dl) = (ODsample/ODstandard)× 200mg/dl
Glucose content (mg / dl) = (OD sample / OD standard ) 200 mg / dl
상기 방법으로 내당성 실험한 결과, 배체 도라지에서 글루코오즈 내당성이 다소 양호하게 나타났지만 큰 차이는 없었으며, 전체적으로 도라지는 내당성이 뛰어남을 확인할 수 있었다. 특히 동결건조, 자연건조보다 열풍건조 및 마이크로웨이브 건조에서 내당성이 우수함을 알 수 있었다(표 13 참조).
As a result of the endurance test by the above method, the glucose tolerance in the platycodon was somewhat good but there was no significant difference, and it was confirmed that the platycodon was excellent in endurance. In particular, it was found that the resistance to frost was superior in freeze drying, hot air drying and microwave drying than in natural drying (see Table 13).
<< 실시예Example 9> 9>
도라지 추출물의 항균 활성 분석Analysis of Antimicrobial Activity of Platycodon grandiflorum Extract
나아가 본 발명자들은 도라지 추출물에 항균활성이 있는지를 알아보고자 2배체, 4배체 도라지 추출물을 시료로 하여 기관지질환 균배양용 액체배지(meat extract 1%, tryptone 1%, NaCl 0.5%, glucose 0.2%, yeast extract 0.3%, pepton 0.1% pH7.3)에 첨가하여 항균효과를 조사하였다. 세균배양용 배지는 blood agar base (Difco 0045)를 변형하여 이용하였으며, 항균활성 검정은 한천배지확산법(disk agar plate diffusion method)으로 측정한다.The present inventors further investigated the antimicrobial activity of Platycodon grandiflorum extract by using a diploid and tetraploid platycodextrose extract as a sample and using a liquid culture medium for bronchial disease (1% meat extract, 1% tryptone, 0.5% NaCl, 0.2% yeast extract 0.3%, pepton 0.1%, pH 7.3). Bacterial culture medium was modified with blood agar base (Difco 0045). Antimicrobial activity assay was performed by disk agar plate diffusion method.
즉, 각 시험미생물에 적합한 배지에 107 CFU/mL 농도로 시험미생물을 배양한 soft agar를 페트리디시(petri dish)에 분주한 후 페이퍼 디스크(paper disc)를 올려놓고 시료 추출물 40 μL씩 분주 후 배양하여 저해환의 생성을 관찰하였다. 24시간 이내에 저해환이 생성된 경우 항균활성이 양성인 것으로 판정하였으며, 저해환의 직경을 측정한 후 비교하였다. 하기 표 14는 본 발명의 도라지 항균활성 실험에 사용한 3가지 균주 종류 및 배양 조건을 기재한 것이다.
That is, a soft agar in which test microorganisms were cultured at a concentration of 10 7 CFU / mL in a medium suitable for each test microorganism was dispensed into a petri dish, and a paper disc was placed on the petri dish. 40 μL of the sample extract was dispensed And the formation of inhibitory rings was observed. When the inhibitory ring was generated within 24 hours, the antimicrobial activity was judged to be positive, and the diameter of the inhibitory ring was measured and compared. Table 14 below shows the three kinds of strains and the culture conditions used in the platycodon microbial activity test of the present invention.
3 종류의 기관지질환 유발 세균에 대한 항균활성 결과, 4배체 도라지 추출물이 2배체 도라지와 비교하여 상대적으로 다소 활성이 높았으며, 특히 클렙시엘라 폐렴균(Klebsiella pneumoniae subsp. pneumoniae)에서는 현저히 높은 활성을 나타냄을 알 수 있었다(도 5 내지 7 참조).
As a result of antimicrobial activity against three kinds of bronchial disease - causing bacteria, the tetraploid phytophagous extract was relatively more active than the diploid bellflower, and Klebsiella pneumoniae subsp. pneumoniae ) (see Figs. 5 to 7).
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (9)
상기 추출물은 물, 유기용매 또는 이들의 혼합 용매 추출물인 것을 특징으로 하는 항균용 약학적 조성물.The method according to claim 1,
Wherein the extract is water, an organic solvent, or a mixed solvent thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130082310A KR101705547B1 (en) | 2013-07-12 | 2013-07-12 | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130082310A KR101705547B1 (en) | 2013-07-12 | 2013-07-12 | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150007810A KR20150007810A (en) | 2015-01-21 |
KR101705547B1 true KR101705547B1 (en) | 2017-02-13 |
Family
ID=52570634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130082310A KR101705547B1 (en) | 2013-07-12 | 2013-07-12 | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101705547B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021085872A1 (en) * | 2019-10-31 | 2021-05-06 | 한국 한의학 연구원 | Composition, comprising salvia plebeia r. br. extract as active ingredient, for inhibiting tumor growth |
KR20220046810A (en) | 2020-10-08 | 2022-04-15 | 롯데푸드 주식회사 | Composition for preventing or treating respiratory function damage caused by fine dust using citrus fruits peel and method for preparing the same |
KR20230077926A (en) | 2021-11-26 | 2023-06-02 | 충남대학교산학협력단 | Antimicrobial and plastic-free wet tissue containing natural extracts |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101976998B1 (en) | 2018-10-18 | 2019-05-10 | 한국수목원관리원 | The method for preparing a Platycodon grandiflorum extract using a high pressure enzyme treatment and a composition having antioxidant or α-glucosidase inhibiting activity |
KR101976999B1 (en) | 2018-10-18 | 2019-05-10 | 한국수목원관리원 | The method for preparing a Platycodon grandiflorum extract using a complex enzyme and a composition for improving antioxidant, whitening or wrinkles containing the same |
KR102107222B1 (en) | 2019-12-27 | 2020-05-28 | 임영지 | Chicken feet granular using nine times steaming platycodon grandiflorum and the manufacturing method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100314999B1 (en) * | 1998-07-02 | 2002-03-21 | 이영춘 | Herbal Medicine for the Treatment of Antibacterial and Inflammatory Diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101259421B1 (en) | 2012-09-14 | 2013-04-30 | (주)휴벳 | Method for producing balloonflower yanggaeng containing spray-dried balloonflower extract improving cognitive function |
-
2013
- 2013-07-12 KR KR1020130082310A patent/KR101705547B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100314999B1 (en) * | 1998-07-02 | 2002-03-21 | 이영춘 | Herbal Medicine for the Treatment of Antibacterial and Inflammatory Diseases |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021085872A1 (en) * | 2019-10-31 | 2021-05-06 | 한국 한의학 연구원 | Composition, comprising salvia plebeia r. br. extract as active ingredient, for inhibiting tumor growth |
KR20220046810A (en) | 2020-10-08 | 2022-04-15 | 롯데푸드 주식회사 | Composition for preventing or treating respiratory function damage caused by fine dust using citrus fruits peel and method for preparing the same |
KR20230077926A (en) | 2021-11-26 | 2023-06-02 | 충남대학교산학협력단 | Antimicrobial and plastic-free wet tissue containing natural extracts |
Also Published As
Publication number | Publication date |
---|---|
KR20150007810A (en) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ramírez-Rodríguez et al. | Ethnobotanical, nutritional and medicinal properties of Mexican drylands Cactaceae Fruits: Recent findings and research opportunities | |
KR101135576B1 (en) | Compositions for prevention and improvement of cancer containing the extracts of native plants as an active ingredient | |
KR101705547B1 (en) | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract | |
KR101959986B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
KR101705548B1 (en) | Composition for enhancing immune response comprising extract of Apios americana Medikus or fermented extract of the same | |
KR101817055B1 (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
KR101682916B1 (en) | Composition comprising steamed and fermented Lycium chinense extract with increased anti-inflammatory or antioxidant activity and preparation method thereof | |
KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
KR20170053536A (en) | Beverages for preventing respiratory disease and hyperlipidemia containing Platycodon grandiflorum and its preparing method | |
KR101768612B1 (en) | Food composition for improving liver function and method of health tea using thereof | |
KR20170077980A (en) | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. | |
KR101889331B1 (en) | A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR20190035139A (en) | A ccosmetic or food composition comprising ligularia senocephala extract and method of a hangover beverage using thereof | |
KR100417243B1 (en) | Pharmaceutical composition comprising the extract of Phyllostachys nigra var. henonis having anti-inflammatory activity for the prevention and treatment of inflammatory disease | |
KR102064516B1 (en) | An antibacterial composition comprising an leaf and root extract of cudrania tricuspidata, and extract of licorice | |
KR101962893B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
KR102179849B1 (en) | Anti-inflammatory composition comprising extract of Polyopes affinis | |
KR101817053B1 (en) | Composition for anti-oxidant or anti-cancer or anti-obesity or immune-enhancing containing Codonopsis lanceolata extract | |
KR101624293B1 (en) | Composition for enhancing immune response comprising extract of Benincasa hispida Cogniaux or fermented extract of the same | |
KR20150037774A (en) | Preparation of clove having enhanced antioxidative effect | |
KR20200101114A (en) | Food composition comprising Chrysanthemum zawadskii var extract | |
KR102673407B1 (en) | Composition for prevention, improvement or treatment of inflammation or sepsis, comprising fermented Codonopsis lanceolata extract as an active ingredient | |
KR20110118748A (en) | Compositions for prevention and improvement of cancer containing the extracts of ligularia fischeri var. spiciformis nakai as an active ingredient | |
KR101852032B1 (en) | Beverages for preventing hyperlipidemia containing Platycodon grandiflorum and its preparing method | |
KR20190048323A (en) | Ginsenoside composition for treating, improving, or preventing inflammatory disease, and method for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
E902 | Notification of reason for refusal | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20200212 Year of fee payment: 4 |